Other Deals

Biocon Biologics to offer 15% stake to Serum Institute Life Sciences

Economic Times  

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, will offer about 15% stake to Serum Institute Life Sciences Pvt Ltd (SILS), a subsidiary of Serum Institute of India, at a post-money valuation of $4.9 billion. In return, BBL will get committed access to 100 million doses of vaccines annually for 15 years and commercialisation rights of SILS' vaccine portfolio - including Covid-19 vaccines - for global markets, primarily from SILS' upcoming vaccine facility in Pune. BBL will generate a committed revenue stream and related margins, starting from the second half of FY23. The company said Adar Poonawalla, CEO of Serum Institute of India (SII), will have a Board seat in BBL. BBL will issue shares and receive the contemplated rights through a merger with Covidshield Technologies Pvt Ltd (CTPL), a wholly owned subsidiary of SILS. The two companies will enter Service Level Agreements (SLAs) for manufacturing and distribution of the vaccines and antibodies.

Want to receive such news items in your inbox? Click Here to sign up for a trial.

2021 © TSJ Media Pvt Ltd. All rights reserved.